See more : Think Research Corporation (THNK.V) Income Statement Analysis – Financial Results
Complete financial analysis of Trevena, Inc. (TRVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trevena, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bankinvest – Europa Small Cap Aktier KL (BAIESCA.CO) Income Statement Analysis – Financial Results
- Basic Energy Services, Inc. (BASX) Income Statement Analysis – Financial Results
- Odakyu Electric Railway Co., Ltd. (ODERF) Income Statement Analysis – Financial Results
- Complex Micro Interconnection Co.,Ltd. (6835.TW) Income Statement Analysis – Financial Results
- Surgical Science Sweden AB (publ) (SUSRF) Income Statement Analysis – Financial Results
Trevena, Inc. (TRVN)
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.13M | -418.00K | 567.00K | 3.07M | 31.00K | 5.73M | 0.00 | 3.75M | 6.25M | 0.00 | 134.98K | 807.60K | 2.42M |
| Cost of Revenue | 1.67M | 3.02M | 954.00K | 182.00K | 108.00K | 0.00 | 490.00K | 0.00 | 44.07M | 40.55M | 18.76M | 13.29M | 0.00 |
| Gross Profit | 1.46M | -3.44M | -387.00K | 2.89M | -77.00K | 5.73M | -490.00K | 3.75M | -37.82M | -40.55M | -18.63M | -12.49M | 2.42M |
| Gross Profit Ratio | 46.56% | 822.01% | -68.25% | 94.07% | -248.39% | 100.00% | 0.00% | 100.00% | -605.18% | 0.00% | -13,800.00% | -1,546.24% | 100.00% |
| Research & Development | 16.33M | 18.21M | 13.43M | 13.12M | 13.29M | 15.82M | 48.97M | 89.96M | 44.07M | 40.55M | 18.76M | 13.29M | 15.11M |
| General & Administrative | 0.00 | 0.00 | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.41M | 34.73M | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Other Expenses | 0.00 | 2.71M | 337.00K | 416.00K | 2.25M | 459.00K | 614.00K | -711.00K | 92.93K | 184.02K | 1.25K | 122.79K | 0.00 |
| Operating Expenses | 38.41M | 52.94M | 51.54M | 32.37M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Cost & Expenses | 38.41M | 55.96M | 52.49M | 32.55M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Interest Income | 2.25M | 451.00K | 162.00K | 240.00K | 418.00K | 1.00M | 679.00K | 743.00K | 331.21K | 17.37K | 884.00 | 754.00 | 3.54K |
| Interest Expense | 0.00 | 1.26M | 1.00K | 29.00K | 931.00K | 2.23M | 2.78M | 1.74M | 334.37K | 70.65K | 149.76K | 193.74K | 74.22K |
| Depreciation & Amortization | 893.00K | 864.00K | 841.00K | 830.00K | 863.00K | 645.00K | 490.00K | 246.00K | 207.90K | 239.39K | 706.78K | 787.52K | 801.58K |
| EBITDA | -35.29M | -55.51M | -51.08M | -28.66M | -25.61M | -28.43M | -68.12M | -101.01M | -50.62M | -49.71M | -22.64M | -14.65M | -14.95M |
| EBITDA Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -74,961.29% | -482.27% | 0.00% | -2,727.55% | -809.94% | 0.00% | -16,770.17% | -1,820.09% | -617.21% |
| Operating Income | -35.29M | -56.38M | -51.93M | -29.49M | -26.58M | -30.50M | -70.39M | -102.28M | -50.62M | -49.95M | -23.35M | -15.61M | -15.75M |
| Operating Income Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -85,741.94% | -532.07% | 0.00% | -2,727.55% | -809.94% | 0.00% | -17,295.37% | -1,932.90% | -650.46% |
| Total Other Income/Expenses | -4.68M | 2.71M | 337.00K | 416.00K | 1.71M | 459.00K | -3.25M | -711.00K | 92.76K | 249.13K | 93.85K | -25.62K | -59.79K |
| Income Before Tax | -39.97M | -53.67M | -51.59M | -29.07M | -24.87M | -30.04M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Income Before Tax Ratio | -1,279.07% | 12,839.71% | -9,098.41% | -947.18% | -80,229.03% | -524.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| Income Tax Expense | 318.00K | -2.71K | -428.00K | 300.00K | 3.19M | 745.00K | 3.39M | -246.00K | -207.90K | 254.67K | 151.00K | 316.53K | 74.22K |
| Net Income | -40.29M | -53.67M | -51.16M | -29.37M | -28.06M | -30.78M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Net Income Ratio | -1,289.25% | 12,839.07% | -9,022.93% | -956.96% | -90,503.23% | -537.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| EPS | -54.51 | -14.88 | -7.82 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| EPS Diluted | -54.51 | -14.88 | -7.77 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| Weighted Avg Shares Out | 739.05K | 3.61M | 6.54M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
| Weighted Avg Shares Out (Dil) | 739.05K | 3.61M | 6.58M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
Trevena Reports Third Quarter 2024 Results and Provides Business Update
CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third...
Trevena Announces Receipt of Nasdaq Delisting Notification
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the...
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones
What's Going On With Neurological Disease Focused Trevena On Thursday?
Shares of Trevena Inc TRVN are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization
Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)
Trevena, Inc. (NASDAQ:TRVN – Free Report) – HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Trevena in a research report issued to clients and investors on Thursday, May 16th. HC Wainwright analyst D. Tsao now expects...
Trevena Reports First Quarter 2024 Results and Provides Business Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it...
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it...
Source: https://incomestatements.info
Category: Stock Reports